Affordable Access

Access to the full text

Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review

Authors
  • Johnston, Karissa M.1
  • Walker, David R.2
  • Lakzadeh, Pardis1
  • 1 Broadstreet Health Economics and Outcomes Research, Vancouver, BC, Canada , Vancouver (Canada)
  • 2 Astellas Pharma Global Development, Inc., Northbrook, IL, USA , Northbrook (United States)
Type
Published Article
Journal
Advances in Therapy
Publisher
Springer Healthcare
Publication Date
Feb 04, 2019
Volume
36
Issue
3
Pages
548–562
Identifiers
DOI: 10.1007/s12325-019-0880-8
Source
Springer Nature
Keywords
License
Green

Abstract

IntroductionThe objective was to identify the most commonly used patient-reported outcome (PRO) instruments for overactive bladder (OAB), determine which are the most useful for measuring burden in OAB and characterize the findings of recent studies that have employed PRO instruments to assess OAB symptoms and the effects of treatment.MethodsA systematic search of OAB literature published between January 2006 and November 2017 using Medline/PubMed and EMBASE databases.ResultsOf 3425 abstracts and 500 full-text articles reviewed, 58 studies (both clinical trials and observational studies) were included in the review. The most commonly used PRO instruments were the OAB Questionnaire (OAB-q; 64%), followed by the King’s Health Questionnaire (KHQ; 31%) and the Patient Perception of Bladder Condition (PCBC; 21%). Synthesis of data from studies using the OAB-q showed that OAB treatment with antimuscarinics, mirabegron and onabotulinumtoxinA all improve health-related quality of life (HRQoL) and symptoms beyond the benefits observed with placebo. The OAB-q could detect dose–response relationships in some studies and demonstrated there were no significant differences across therapies from different drug classes.ConclusionThe HRQoL burden of OAB and response to treatment can be reliably measured by PRO instruments, and the OAB-q is the most commonly used instrument in OAB, particularly in clinical trials of OAB interventions. These data will be useful to provide benchmarks of burden levels for PRO scores obtained among those on contemporary therapies for comparison with outcomes from patients managed with emerging treatments.FundingAstellas Pharma Global Development, Inc.

Report this publication

Statistics

Seen <100 times